52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation For Orencia®
Celgene Plans To Transfer Listing Of Celgene’S Contingent Value Rights Following Closing Of Deal With Bristol-Myers Squibb
Bristol-Myers Squibb Co Says It Expects No Further Extension Of Expiration Date For Exchange Offers For Celgene Corp Notes
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.
Biotechnology & Drugs
430 E 29th St Fl 14
Chairman of the Board, Chief Executive Officer
Charles A. Bancroft
Chief Financial Officer, Executive Vice President - Global Business Operations
Ann Powell Judge
Chief Human Resource Officer, Senior Vice President
Executive Vice President, General Counsel
Christopher S. Boerner
Executive Vice President and Chief Commercial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla.
Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.
Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Maler)
U.S. drugmaker Bristol-Myers Squibb Co <BMY.N> reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.
Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients.
About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday...
Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.
Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.
Bristol-Myers Squibb Co <BMY.N>, which is set to buy biotechnology company Celgene Corp <CELG.O> for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.
Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.
Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.
Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).
Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.
Puerto Rico's federally created financial oversight board on Tuesday began filing the first round of scores of lawsuits seeking to recover money the bankrupt U.S. commonwealth paid to bondholders, businesses and others.
U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.
Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.